What are the milestones to be reached for an academic asset?

What are the milestones to be reached for an academic asset?

How to valuate an early-stage though promising asset? To what extent do experimented actors help the bio-entrepreneur to aim for a realistic maturation and validation roadmap? How do they help the managing team to understand value inflection points? How do the industry players (pharma, biotech, VC) handle this issue of granting of value to those assets? How could industrial players help academic institutions and TTOs avoid making mistakes at the very early development stages?

Tanya Moore

Business Development Executive
United Kingdom
Cancer Research UK

Gary Breit

CEO
USA
Breit Ideas

Matthieu Coutet

Vice President
France
ADVENT FRANCE BIOTECHNOLOGIES

Benjamin Soffer

Head of Strategic Corporate Partnerships
United Kingdom
King’s College
  • No products in the cart.